SGAM
ANIK icon

Smith Group Asset Management’s Anika Therapeutics ANIK Stock Holding History

Smith Group Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,360
Closed -$41K – 407
2019
Q1 		$41K Sell
1,360
-80
-6% -$2.74K ﹤0.01% 311
2018
Q4 		$48K Hold
1,440
– – ﹤0.01% 302
2018
Q3 		$61K Hold
1,440
– – ﹤0.01% 292
2018
Q2 		$46K Hold
1,440
– – ﹤0.01% 337
2018
Q1 		$72K Sell
1,440
-50
-3% -$2.83K ﹤0.01% 316
2017
Q4 		$80K Hold
1,490
– – ﹤0.01% 296
2017
Q3 		$86K Sell
1,490
-1,410
-49% -$73.7K ﹤0.01% 295
2017
Q2 		$143K Sell
2,900
-1,330
-31% -$61.2K ﹤0.01% 281
2017
Q1 		$184K Sell
4,230
-2,030
-32% -$96.9K 0.01% 278
2016
Q4 		$306K Sell
6,260
-200
-3% -$9.25K 0.01% 220
2016
Q3 		$309K Buy
6,460
+130
+2% +$6.42K 0.01% 216
2016
Q2 		$340K Sell
6,330
-65,070
-91% -$3.07M 0.01% 210
2016
Q1 		$3.19M Buy
71,400
+250
+0.4% +$10.1K 0.1% 105
2015
Q4 		$2.71M Buy
71,150
+69,440
+4,061% +$2.66M 0.08% 118
2015
Q3 		$54K Sell
1,710
-113
-6% -$3.94K ﹤0.01% 283
2015
Q2 		$59K Sell
1,823
-91,184
-98% -$3.25M ﹤0.01% 276
2015
Q1 		$3.83M Sell
93,007
-5,120
-5% -$207K 0.13% 113
2014
Q4 		$4M Sell
98,127
-2,840
-3% -$111K 0.14% 118
2014
Q3 		$3.7M Buy
100,967
+653
+0.7% +$28.2K 0.14% 122
2014
Q2 		$4.65M Sell
100,314
-15,909
-14% -$708K 0.17% 104
2014
Q1 		$4.78M Sell
116,223
-16,169
-12% -$601K 0.18% 100
2013
Q4 		$5.05M Sell
132,392
-18,499
-12% -$571K 0.19% 96
2013
Q3 		$3.6M Sell
150,891
-15,582
-9% -$350K 0.15% 116
2013
Q2 		$2.83M Buy
+166,473
New +$2.4M 0.12% 142

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Smith Group Asset Management's ANIK Position: Q2 2019 in Review

Smith Group Asset Management sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 1,360 shares — an estimated $41K sold.

Smith Group Asset Management first reported a position in ANIK in Q2 2013 and held it in 24 quarters. The position peaked at $5.05M in Q4 2013. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Smith Group Asset Management reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Smith Group Asset Management sold 1,360 Anika Therapeutics shares in Q2 2019, an estimated $41K.
  • Smith Group Asset Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 24 quarters.
  • Smith Group Asset Management's Anika Therapeutics position peaked at $5.05M in Q4 2013.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Smith Group Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.